Pharmacogenomics in epilepsy care across Asia
Abstract
The selection of anti‐seizure medications (ASMs) in epilepsy remains largely empirical, leading to varied efficacy and a significant burden of adverse drug reactions (ADRs). A pharmacogenomic‐based strategy can be used to personalize ASM selection, as it incorporates genetic information into clinical decision‐making. While more than 50 gene–drug associations have been reported in epilepsy, few pairs have strong, replicated evidence with clinical applicability. In Asia, key variants include HLA‐B15:02 and HLA‐A31:01, which are associated with severe cutaneous adverse reactions (SCARs), and CYP2C9 and CYP2C19 variants, which affect drug metabolism. These pairs have influenced regional regulatory policies, with HLA‐B15:02 screening widely implemented prior to carbamazepine use. However, routine practice is still heterogenous due to variability in allele frequencies, healthcare infrastructure, and policy frameworks across countries. We propose evidence‐based criteria for clinical implementation of pharmacogenomic markers, emphasizing replicated associations, clinical significance, actionable alternatives, and cost‐effectiveness. Currently, HLA‐B15:02 possesses the strongest evidence for mandatory screening, while others remain advisory due to limited outcome data. Real‐world challenges include incomplete risk prediction from single‐allele testing, overlapping drug hypersensitivity profiles, and workflow limitations, particularly in urgent care settings. In lower resource regions, test availability and access are additional hurdles to implementation. Future research should include multiethnic datasets, improved health‐economic evaluations, and integration of genomic data into clinical decision‐support systems. Advancing polygenic and multi‐omics approaches could improve prediction of treatment response and toxicity.Keywords
This publication has 52 references indexed in Scilit:
- Advancing the science of genomic learning healthcare systemsLearning Health Systems, 2025
- Medical Liability in Asia and Australasia2022
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 UpdateClinical Pharmacology & Therapeutics, 2020
- HLA‐B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin‐Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan ProjectClinical Pharmacology & Therapeutics, 2019
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese PopulationJAMA Neurology, 2018
- Clinical Pharmacogenetics Implementation Consortium Guideline forHLAGenotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateClinical Pharmacology & Therapeutics, 2018
- Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working GroupClinical Pharmacology & Therapeutics, 2017
- Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation ServicesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Pharmacovigilance in Hong Kong2014
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisJAMA Dermatology, 2013